Loading
A phase 3 trial of Cladribine, Daunorubicin and Mitoxantrone in Acute myeloid leukaemia, run by dr hab. n. med. Agnieszka Wierzbowska, with a status the registry has not verified recently.
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02072811 by dr hab. n. med. Agnieszka Wierzbowska, with 400 participants planned, started 2014-02 and due to reach its primary completion in 2018-02. Interventions recorded: DAC, CLAG, Consolidation, I HAM cycle, II Consolidation HiDAraC, Consolidation, III HiDAraC cycle. Conditions recorded: Acute Myeloid Leukemia.
Linked to the drug Cladribine because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Cladribine, Mitoxantrone, Daunorubicin and the tag pipeline.
Shares Mitoxantrone, Daunorubicin, Acute myeloid leukaemia and the tag pipeline.
Shares Daunorubicin, Acute myeloid leukaemia and the tag pipeline.
Shares Mitoxantrone, Daunorubicin, Acute myeloid leukaemia and the tag pipeline.
Shares Mitoxantrone, Daunorubicin and the tag pipeline.
Shares Cladribine and the tag pipeline.
Shares Mitoxantrone, Acute myeloid leukaemia and the tag pipeline.
Shares Mitoxantrone, Daunorubicin, Acute myeloid leukaemia and the tag pipeline.